Safety and Efficacy Study of JNJ-64304500 in Participants With Moderately to Severely Active Crohn's Disease
Phase 2
Completed
- Conditions
- Crohn Disease
- Interventions
- First Posted Date
- 2016-08-24
- Last Posted Date
- 2023-02-17
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 388
- Registration Number
- NCT02877134
Study to Assess the Bioequivalence of Ibrutinib 140 Milligram (mg) Tablet to 140 mg IMBRUVICA Capsule
- First Posted Date
- 2016-08-24
- Last Posted Date
- 2017-03-10
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 103
- Registration Number
- NCT02877225
Study Comparing Daratumumab, Lenalidomide, Bortezomib, and Dexamethasone (D-RVd) Versus Lenalidomide, Bortezomib, and Dexamethasone (RVd) in Subjects With Newly Diagnosed Multiple Myeloma
Phase 2
Completed
- Conditions
- Multiple Myeloma
- Interventions
- First Posted Date
- 2016-08-22
- Last Posted Date
- 2023-07-27
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 224
- Registration Number
- NCT02874742
A Study to Assess the Bioequivalence of the Metformin Component of the Fixed Dose Combination Tablet of Canagliflozin and Metformin Extended Release With Respect to Metformin XR Tablet Coadministered With Canagliflozin in Healthy Fed and Fasted Participants
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2016-08-12
- Last Posted Date
- 2017-02-09
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 44
- Registration Number
- NCT02865668
Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of JNJ-64565111 in Type 2 Diabetes Mellitus (T2DM)
- First Posted Date
- 2016-08-11
- Last Posted Date
- 2023-07-03
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 24
- Registration Number
- NCT02862431
Pharmacokinetic, Safety, and Tolerability Study of Intranasally Administered Esketamine in Elderly Japanese, and Healthy Younger Adult Japanese Subjects
- First Posted Date
- 2016-08-05
- Last Posted Date
- 2017-03-14
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 37
- Registration Number
- NCT02857777
Sodium-glucose Co-transporter 2 (SGLT2) Inhibitor Risk of Below-Knee Lower Extremity Amputation: A Retrospective Cohort Study Using a Large Claims Database in the United States
Completed
- Conditions
- Diabetes Mellitus, Type 2
- First Posted Date
- 2016-08-05
- Last Posted Date
- 2017-08-30
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 127690
- Registration Number
- NCT02857764
An Efficacy and Safety Study of Niraparib in Men With Metastatic Castration-Resistant Prostate Cancer and DNA-Repair Anomalies
- First Posted Date
- 2016-08-03
- Last Posted Date
- 2023-11-13
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 289
- Registration Number
- NCT02854436
Dose Escalation Study of JNJ-54767414 (Daratumumab) in Chinese Participants With Relapsed or Refractory Multiple Myeloma Who Failed at Least 2 Prior Lines of Systemic Therapy
- First Posted Date
- 2016-08-02
- Last Posted Date
- 2020-11-16
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 50
- Registration Number
- NCT02852837
A Study to Assess the Bioequivalence of the Metformin Component of the Fixed Dose Combination Tablet of Canagliflozin and Metformin Extended Release With Respect to Metformin Extended Release Tablet Coadministered With Canagliflozin in Healthy Fed and Fasted Participants
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2016-08-01
- Last Posted Date
- 2016-12-02
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 44
- Registration Number
- NCT02851212
© Copyright 2025. All Rights Reserved by MedPath